LCP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25099860	0.79	6/20
SCHEMBL25099370	0.78	6/20
SCHEMBL25100132	0.75	6/20
SCHEMBL25099366	0.74	6/20
SCHEMBL23988251	0.73	6/20
SCHEMBL25099339	0.72	6/20
SCHEMBL25099349	0.72	6/20
SCHEMBL25099577	0.72	6/20
SCHEMBL25099550	0.72	6/20
SCHEMBL25099328	0.71	6/20
SCHEMBL25099359	0.71	6/20
SCHEMBL25099579	0.71	6/20
SCHEMBL25099448	0.71	6/20
SCHEMBL25100233	0.70	6/20
SCHEMBL25099590	0.70	6/20
SCHEMBL25099897	0.70	6/20
SCHEMBL25099827	0.69	6/20
SCHEMBL25099431	0.69	6/20
SCHEMBL25099444	0.69	6/20
SCHEMBL25099904	0.69	6/20

Clinical trials — most relevant to LCP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
CISH Inactivated TILs in the Treatment of NSCLC	PHASE1/PHASE2	WITHDRAWN
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma	PHASE2	COMPLETED
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma	PHASE2	ACTIVE_NOT_RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer	PHASE1	RECRUITING
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)	PHASE1	RECRUITING
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC	EARLY_PHASE1	UNKNOWN
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy	nan	UNKNOWN
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)	nan	COMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Novel Genetic Disorders of the Immune System	nan	RECRUITING
Urinary G3BP as a Novel Biomarker in Lupus Nephritis	nan	NOT_YET_RECRUITING
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Efferocytosis and Genomic Polymorphism in Autoimmune Diseases	nan	UNKNOWN
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study	nan	COMPLETED
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Role of SLURP-1 in Melanoma and Melanoma Stem Cells	nan	UNKNOWN
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects	nan	WITHDRAWN
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)	nan	ACTIVE_NOT_RECRUITING
Methotrexate Alone vs Combination With Excimer Light in Nail Psoriasis	nan	UNKNOWN
Protective Immune Mechanisms in Alcoholic Hepatitis	nan	COMPLETED
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD)	nan	NOT_YET_RECRUITING
Effects of Epigenetic Regulation in Chronic Pelvic Pain Syndrome	nan	ACTIVE_NOT_RECRUITING
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome	nan	COMPLETED
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a LCP2 binder may also engage these)

Protein	Name	Similarity
Q60787	—	1.000	Q60787 →
Q9QUN3	—	0.993	Q9QUN3 →
Q4KM52	—	0.991	Q4KM52 →
Q8WV28	—	0.990	Q8WV28 →
O15117	—	0.988	O15117 →
Q9YGC1	—	0.987	Q9YGC1 →
O35601	—	0.980	O35601 →
D3ZIE4	—	0.980	D3ZIE4 →
Q8N4X5	—	0.979	Q8N4X5 →
A1X283	—	0.979	A1X283 →
O89032	—	0.978	O89032 →
GAB1	GRB2-associated-binding protein 1	0.978	landscape →
O54967	—	0.978	O54967 →
Q9Z1S8	—	0.977	Q9Z1S8 →
Q4V8Y7	—	0.977	Q4V8Y7 →
Q5XI07	—	0.977	Q5XI07 →
Q8CG79	—	0.977	Q8CG79 →
Q13625	—	0.977	Q13625 →
Q17R10	—	0.977	Q17R10 →
Q7Z7G1	—	0.976	Q7Z7G1 →
O94913	—	0.976	O94913 →
Q14511	—	0.976	Q14511 →
D3ZUI5	—	0.976	D3ZUI5 →
D4AB98	—	0.976	D4AB98 →
Q96D71	—	0.976	Q96D71 →
A6QLU3	—	0.976	A6QLU3 →
Q56A36	—	0.976	Q56A36 →
Q96KQ4	—	0.976	Q96KQ4 →
Q62523	—	0.976	Q62523 →
Q8C180	—	0.976	Q8C180 →